NCT07195695
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 28 versions: 28 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 202 → 205 locations
- Minor Study sites: 202 to 203
- Minor Site details revised at 2 of 202 sites
- Minor Study sites revised (202)
- Notable Eligibility criteria expanded, about 21 words
- Primary endpoints: details revised at 1 of 1 entry
- Study sites revised (202)
- Minor Study sites revised (202)v23
- Minor Trial sites expanded: 198 → 202 locationsv22
- Minor Study sites: 199 to 198v21
- Minor Site details revised at 9 of 199 sitesv20
- Minor Study sites: 200 to 199v19
- Minor Study sites: 199 to 200v18
- Minor Study sites: 197 to 199v17
- Minor Study sites: 196 to 197
- Study description expanded, about 139 words
- Study title shortened, about 4 words
- Minor Trial sites expanded: 192 → 196 locationsv15
- Minor Study sites: 198 to 192v14
- Minor Study sites: 185 to 198v13
- Minor Study sites: 184 to 185v12
- Minor Study sites: 178 to 184v11
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 177 to 178
- Start date changed from estimate of Feb 6, 2026 to Jan 16, 2026
- Notable Start date: Dec 29, 2025 to Feb 6, 2026
- Study sites: 175 to 177
- Minor Study sites: 176 to 175v8
- Minor Start date: Dec 5, 2025 to Dec 29, 2025
- Site contacts updated at 25 of 176 sites
- Minor Study sites: 168 to 176v6
- Minor Study sites: 166 to 168v5
- Minor Study sites: 159 to 166v4
- Minor Study sites: 157 to 159v3
- Minor Study completion date: May 22, 2034 to Sep 2, 2036
- Study sites revised (157)
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Disease-free survival (DFS) by investigator's assessment
Timeframe: up to 8 years and 5 months
Secondary (2)
Key secondary endpoint: Overall survival (OS), defined as the time from randomization until death from any cause
Occurrence of trial-related Adverse Events (AEs) ≥ Grade 3 from first treatment administration (or from randomization for patients in the observation arm) until the earliest of tumor recurrence or 3 years since treatment start
Arms and interventions
Zongertinib treatment armExperimental
Standard of Care (SoC) treatment armActive comparator
Drugs: Zongertinib, Pembrolizumab, Atezolizumab, Durvalumab, Nivolumab
Sites
205 sites in 28 countries
United States 29, China 28, Japan 25, Spain 14, Germany 9, France 8, Italy 8, South Korea 8, Brazil 7, Turkey (Türkiye) 7, Taiwan 6, United Kingdom 6, Argentina 5, Australia 5, Israel 5, Mexico 5, Hong Kong 4, Portugal 4, Romania 4, Belgium 3, Canada 3, Greece 3, Austria 2, Chile 2, Sweden 2, Denmark 1, Netherlands 1, Singapore 1